SL
Labidi-Galy, Sana Intidhar
Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
---|---|---|---|---|---|---|---|
Window of opportunity with PD1 blockade before chemoradiotherapy for an advanced stage clear cell carcinoma of the cervix | Gynecologic oncology reports | 2024 | 48 | 26 | |||
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting : final analysis of LUCY | Breast cancer research and treatment | 2024 | 33 | 12 | |||
Identification of clinically relevant t cell receptors for personalized t cell therapy using combinatorial algorithms | Nature biotechnology | 2024 | 60 | 12 | |||
H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours | Nature communications | 2024 | 75 | 12 | |||
Characteristics of long-survivor metastatic melanoma after polychemotherapy and interferon : a retrospective study | Swiss medical weekly | 2023 | 28 | 12 | |||
Nab-PIPAC: a phase IB study protocol of intraperitoneal cisplatin and nab-paclitaxel administered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity | BMJ open | 2023 | 364 | 52 | |||
Changes of health-related quality of life 6 months after high-risk oncological upper gastrointestinal and hepatobiliary surgery: a single-centre prospective observational study (ChangeQol Study) | BMJ open | 2023 | 110 | 83 | |||
Clonal expansion of intra-epithelial T cells in breast cancer revealed by spatial transcriptomics | International journal of cancer | 2023 | 397 | 49 | |||
The clinical challenges of homologous recombination proficiency in ovarian cancer : from intrinsic resistance to new treatment opportunities | Cancer drug resistance | 2023 | 27 | 18 | |||
Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer | iScience | 2022 | 176 | 83 | |||
Traitements intrapéritonéaux de la carcinose ovarienne : proposition d’algorithmes décisionnels | Revue médicale suisse | 2022 | 106 | 56 | |||
Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer | Seminars in cancer biology | 2021 | 11 | 12 | |||
Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer | Cancer Cell | 2021 | 223 | 205 | |||
Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm? | Cancer treatment reviews | 2021 | 40 | 25 | |||
Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes | Scientific Reports | 2020 | 283 | 284 | |||
Pathogenesis of ovarian cancer | 2020 | 651 | 469 | ||||
Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation | Gynecologic Oncology Reports | 2020 | 243 | 145 | |||
Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets — a narrative review | Annals of translational medicine | 2020 | 152 | 91 | |||
BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients | Breast Cancer Research and Treatment | 2019 | 389 | 3 | |||
Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors | The Journal of Pathology | 2018 | 850 | 6 | |||
High grade serous ovarian carcinomas originate in the fallopian tube | Nature Communications | 2017 | 465 | 312 | |||
Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer | Journal of Translational Medicine | 2017 | 430 | 185 |